Skip to search formSkip to main contentSkip to account menu

dapagliflozin

Known as: (2S,3R,4R,5S,6R)-2-(4-Chloro-3-(4-ethoxybenzyl)phenyl)-6- (hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol, D-Glucitol, 1,5-anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-, (1S)-, Compd. with (2S)-1,2-propanediol, Hydrate (1:1:1) 
A selective sodium-glucose co-transporter subtype 2 (SGLT2) inhibitor with antihyperglycemic activity. Dapagliflozin selectively and potently… 
National Institutes of Health

Related topics

Related topics

8 relations
24 HR dapagliflozin 10 MG / Metformin hydrochloride 1000 MG Extended Release Oral TabletSodium-Glucose Transporter 2 Inhibitors [MoA]dapagliflozin 10 MGdapagliflozin 10 MG Oral Tablet

Narrower (3)

FarxigaXigduodapagliflozin propanediol

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Клинико-экономическая эффективность применения препарата дапаглифлозин у пациентов с сахарным диабетом 2-го типа в условиях здравоохранения Российской Федерации
Purpose . To evaluate pharmacoeconomic efficiency of dapagliflosin application for intensification of hypoglycemic therapy — in… 
2019
2019
192Effect of dapagliflozin on cardiovascular outcomes in patients with type 2 diabetes according to baseline renal function and albuminuria status: Insights from DECLARE-TIMI 58
Renal dysfunction including both reduced estimated glomerular filtration rate (eGFR) and the presence of albuminuria have… 
2019
2019
Abstract 10643: A Randomised Controlled Trial of Dapagliflozin on Left Ventricular Hypertrophy in Patients With Type Two Diabetes. The DAPA-LVH Trial
Introduction: Patients with diabetes have a two to fourfold increased risk for development of and death from cardiovascular… 
Review
2018
Review
2018
Saxagliptin and Dapagliflozin for type 2 Diabetes mellitus: A Review
Qtern® is a fixed dose combination tablet of Saxagliptin and Dapagliflozin which is indicated for the advancement of glycaemic… 
2018
2018
САХАРНЫЙ ДИАБЕТ 2 ТИПА И СЕРДЕЧНО-СОСУДИСТЫЕ ОСЛОЖНЕНИЯ: МОЖНО ЛИ УЛУЧШИТЬ ПРОГНОЗ НАЗНАЧЕНИЕМ САХАРОСНИЖАЮЩИХ ПРЕПАРАТОВ
Regardless the fact that type 2 diabetes (DM2) is related to higher risk of cardiovascular diseases (CVD) development and… 
Review
2015
Review
2015
POTENTIAL PLACE OF SGLT2 INHIBITORS IN TREATMENT PARADIGMS FOR TYPE 2 DIABETES MELLITUS.
OBJECTIVE Following the first Food and Drug Administration (FDA) approval in 2013, sodium glucose cotransporter 2 (SGLT2… 
2013
2013
Abstract 13165: Dapagliflozin for Reduction of Blood Pressure in Diabetic Patients Inadequately Controlled With Combination Antihypertensive Regimen
Hypertension is a frequent comorbidity of type 2 diabetes (T2D); dual antihypertensive agents (ACEi or ARB plus a second agent… 
2013
2013
Diabetes: Efficacy of dapagliflozin associated with renal function
were lower in dapagliflozin-treated as compared to placebo-treated patients with stage 3 CKD. Creatinine clearance and estimated… 
2013
2013
Abstract 10606: Blood Pressure Reduction With Dapagliflozin in Patients With Type 2 Diabetes and Cardiovascular Disease
Background: Dapagliflozin (DAPA) is a selective SGLT2 inhibitor shown to reduce hyperglycemia and weight in patients with type 2… 
2012
2012
Developing New Drugs for Diabetes and Cardiometabolic Disorders
The range of drugs now available for the treatment of diabetes is unprecedented. However, all the current agents correct…